March 16, 2006 – BioMarin announced that Phenoptin met all endpoints in a Phase III trial against a rare genetic disease; Fisher Scientific, the lab equipment supplier, made a $15 million investment in Nanogen as it moved to market molecular diagnostic tests; Chiron recalled its MMR vaccine because of a high rate of adverse events; Conor Medsystems licensed an anti-inflammatory drug from Novartis for its next generation stents; Valeant Pharma reported positive results from a Phase II test of a hepatitis B drug; Medtronic won an expanded labeling for its cardiac device; Targeted Genetics received FDA permission to expand the protocol for an arthritis drug test; Eisai from Japan reported 11 deaths among participants in a trial of its Alzheimer’s drug, Aricept; and Cephalon moved lower on label worries about Sparlon, an ADHD drug that is awaiting FDA approval. The Centient Biotech 200™ was down 17 points at 4022.06, a loss of .41%. More details...
